Floatz logo

Denifanstat

Solid Malignant Tumor

Sagimet Biosciences Inc.Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

1412 Active assets in the Solid Malignant Tumor cohort.

Asset / SponsorPhaseRating
Nabiximols
Jazz Pharmaceuticals
Phase 3BBB
Inno-206
M.D. Anderson Cancer Center
Phase 2BB
Vitamin B6
M.D. Anderson Cancer Center
Phase 4BB
PROPOFOL
Hong Kong Children's Hospital
Phase 4BB
Rivoceranib
Jiangsu HengRui Medicine Co., Ltd.
Phase 4BB

View all 50 →

Same molecule, other indications

Denifanstat is also rated in:

metabolic dysfunction-associated steatotic liver diseaseDormant
BB
Indicative ·
66 / 100
View asset →
metabolic dysfunction-associated steatohepatitisDormant
BB
Indicative ·
64 / 100
View asset →
metabolic dysfunction-associated steatotic liver diseaseDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →